Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Raises $6.7M in Private Placement

NEW YORK (GenomeWeb) – GeneNews today announced it has accepted subscriptions for a non-brokered private placement of its common shares for gross proceeds of about C$7.2 million (US$6.7 million).

The Toronto-based molecular diagnostics shop will issue 7 million common shares at C$1.03 per share as a result of the placement, which GeneNews announced last week. In a statement, GeneNews Executive Chairman James Howard-Tripp said that the financing provides the company with the resources to build out Innovative Diagnostics Laboratory "as a strong commercialization outlet" for the firm's molecular diagnostic tests for colon cancer, lung cancer, and prostate cancer.

IDL is a CLIA laboratory jointly owned by GeneNews, Health Diagnostics Laboratory, and an unnamed US sales organization.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.